0000706698
false
0000706698
2026-01-29
2026-01-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 29, 2026
UTAH MEDICAL PRODUCTS, INC.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
UTAH
|
| 000-12575
|
| 87-0342734
|
(State or other jurisdiction of
|
| (Commission File Number)
|
| (IRS Employer
|
incorporation or organization)
|
|
|
| Identification No.)
|
|
|
|
|
|
7043 South 300 West
|
|
|
Midvale, Utah
|
| 84047
|
(Address of principal executive offices)
|
| (Zip code)
|
|
|
|
Registrant’s telephone number, including area code:
|
| Phone: (801) 566-1200
|
|
|
|
n/a
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
|
| Emerging growth company ☐
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
|
ITEM 2.02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION
Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated January 29, 2026.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS
The following is filed as an exhibit to this report:
Exhibit
Number*
|
|
Title of Document
|
|
Location
|
Item 99.1
|
| Financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated January 29, 2026.
|
|
|
|
|
|
| This filing
|
_______________________________________
*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UTAH MEDICAL PRODUCTS, INC.
|
|
|
|
|
|
|
Dated: January 29, 2026
| By:
| /s/ Kevin L. Cornwell
|
|
| Kevin L. Cornwell, Chief Executive Officer
|
